Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company’s work in HIV and hepatitis and how her personal background informed her team’s work in developing a Covid-19 treatment.

Improving Customer Experience and Conversion in Healthcare & Life Sciences.

At the upcoming INVEST Digital Health conference in Dallas set for September 28, in collaboration with Health Wildcatters, a panel discussion on the future of pharmacy benefit managers will be part of the larger conversation on employee benefits. AJ Loiacono, CapitalRx CEO, shared his perspective on the topic.

A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to repair and improve manufacturing supply chain issues exposed by the Covid-19 pandemic.

Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.

Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.

“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states.” That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.

“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states.” That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.

A look at how healthcare organizations are collaborating with Microsoft to enhance patient engagement, accelerate healthcare innovation, improve clinical and operational insights, and more.

Microsoft seeks to change the way pharma industry companies use technology to better navigate human resource and supply chain challenges.

By engaging in a dialogue, patients and pharma companies can have a mutually beneficial relationship, Health Union’s Jack Barrette said at HLTH’s patient engagement track, hosted by MedCity News. Not only can patients help mold clinical trials, but they can help companies improve their patient education efforts.

Clinical 2021 is US and EU pharma’s leading event for clinical innovators – join 500+ executive attendees from across the globe to meet and learn virtually.

Did you miss the event? Register for the On-Demand Webinar to learn how digital engagement can solve challenges for both patients and the brand and learn other benefits that will improve patient experience and address multiple barriers to medication adherence.

With more readers and greater engagement in our content than ever, we have many products that can help you reach your customer base through our content, ads, podcasts and online events. Contact us to learn more.

Propeller Health and Novartis received the green light from European regulators to package their products together. The move is one step of many to make digital therapeutics easier to prescribe.

The increased patient-centric focus in drug development by the FDA is highly encouraging and expected to become more mainstream and legislated. 

IBM is stopping the development and sales of the product, which uses Watson AI to help pharmaceutical companies find new drugs, because it wasn’t yielding large enough financial returns, according to a STAT report.

As pharma continues to close the gap between the operational and analytical needs of their business, they can look to other industries for best practices.

The behavioral health epidemic, artificial intelligence and more procedures being done in outpatient settings are some the key 2019 trends that will determine how decision makers purchase technology.

Strategic partnerships are one way for biopharmaceutical companies to expand capabilities and offerings and proactively define their future versus having it defined for them.

A new survey found chief medical information officers believe medication management improvement initiatives have positively impacted patient safety, but factors like workflow variation and a lack of price transparency still compromise patients’ well-being.

Panelists highlight Roche’s acquisition of Flatiron Health in February and use of AI/ML in drug development.

The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.

It’s the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma’s drug development business, particularly in cancer treatment.

A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.

A new report shows a steady growth in so-called “basket studies” in oncology, along with growing interest by the drug industry.

In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.

Shkreli, 35, is serving a seven-year prison term for securities fraud (unrelated to Daraprim). Turing has renamed itself Vyera Pharmaceuticals. But Daraprim, which costs pennies to make and is used to treat the parasitic infection toxoplasmosis still retails for more than $750 per pill, according to drug website GoodRx.com.

The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.

At the ninth annual Health Datapalooza conference in Washington D.C. this week, Scott Gottlieb also provided an update on the pre-certification program, which is scheduled to launch before the end of the year.